Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Hepatology

Volumn 37, Issue 2, 2003, Pages 429-442

  Llovet, Josep M ^a,b   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; AMSACRINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUTAMIDE; GELFOAM; GONADORELIN AGONIST; LOMUSTINE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MENOGARIL; MITOMYCIN C; NILUTAMIDE; OCTREOTIDE; PRAVASTATIN; STREPTOZOCIN; TAMOXIFEN; TRIPTORELIN; UFT; VINCRISTINE; ZINOSTATIN;

ADVANCED CANCER; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; CONSERVATIVE TREATMENT; EVIDENCE BASED MEDICINE; HEPATIC ARTERY LIGATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0037308133     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50047     Document Type: Article

References (89)

1. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001;94:153-156.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Christensen E, Burroughs A, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. HEPATOLOGY 2002;35:519-524.
5. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, et al. Irnproving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1999;276:637-639.
6. Lau J, Loannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
7. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between metaanalysis and large trials. JAMA 1998;279:1089-1093.
8. Cook DJ, Mulrow H, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376-380.
9. Pogue J, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clin Trials 1997;18:580-593.
10. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomized trials. Lancet 1998;351:47-52.
11. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
12. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-126.
13. Jadad A, Moore A, Carroll D, Jenikson C, Reynols J, Gavaghan D, McQuay H. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
14. Bañares R, Albillos A, Rincón D, Alonso S, González M, Ruiz-del-Arbol L, Salcedo M, et al. Endoscopic treatment versus endoscopic plus pharmacological treatment for acute variceal bleeding: a meta-analysis. HEPATOLOGY 2002;35:609-615.
15. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 1998;352:609-613.
16. Kjaergard L, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small trials in meta-analysis. Ann Intern Med 2001;135:982-989.
17. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, Bru C, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. HEPATOLOGY 1999;29:62-67.
18. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188.
20. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUORUM Group. Improving the quality of reports of meta-analysis of randomized controlled trials: the QUORUM statement. Lancet 1999;354:1896-1900.
21. Cochrane Collaboration guidelines for reporting systematic reviews. Available at: http://www.cochrane.dk/cochrane/handbook. Accessed April 2002.
22. Bartolozzi C, Lencioni R, Caramella D, Vignali C, Cioni R, Mazzeo S, Carrai M, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197:812-818.
23. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. HEPATOLOGY 1998,27:67-72.
24. Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma. Cancer 2001;92:1516-1524.
25. Habib N, Salam H, Abd El Latif Abu Media, Isac Anis I, Abd Al Aziz RA, Sarraf C, Mitry R, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002;9:254-259.
26. Shibata T, Limuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331-337.
27. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 1988;94:453-456.
28. Pelletier G, Roche A, Ink O, Anciaux ML, Derby S, Rougier P, Lenoir C, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-184.
29. Group d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
30. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. HEPATOLOGY 1998;27:1578-1583.
31. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, Van Steenbergen W, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998;29:129-134.
32. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. HEPATOLOGY 2002;35:11641171.
33. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, et al. Arterial embolisation of chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
34. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, Fujita M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965-971.
35. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992;31:S1-S6.
36. Okamura J, Kawai S, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992;31:S20-S24.
37. Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1994;33:S97-S102.
38. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994;74:2449-2453.
39. Hatanaka Y, Yamashita Y, Takahashi M, Koga Y, Saito R, Nakashima K, Urata J, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995;195:747-752.
40. Ikeda K, Saitoh S, Koida L, Tsubota A, Arase Y, Chayama K, Kumada H. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995;18:204-210.
41. Ikeda K, Saitoh S, Suzuki Y, Koida L, Tsubota A, Kobayashi M, Arase Y, et al. A prospective randomized administration of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1997;20:202-208.
42. Kwok PC, Lam TW, Chan S, Chung CP, Wong WK, Chan MK, Lo HY, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000;32:955-964.
43. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-891.
44. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-artetial and intravenous use of 4'epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992;15:37-40.
45. Ikeda K, Inoue H, Yano T, Kobayashi H, Nakajo M. Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection. Cancer Chemother Pharmacol 1992;31:S65-S68.
46. Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 1993;16:206-209.
47. Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-1600.
48. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994;33:S93-S96.
49. Yoshikawa M, Saisho H, Ebara M, Iijima T, Iwama S, Endo F, Kimura M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33:S149S152.
50. 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202-2210.
51. Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997;24:S6.
52. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991.
53. Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, Guo YP, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002;8:74-78.
54. Order S, Pajak T, Leibel S, Asbell S, Leichner P, Ettinger D, Stillwagon G, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991;20:953-963.
55. Raoul JL, Guyader D, Bretagne JF, Asbell S, Leichner, Ettinger D, Stillwagon G, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-1787.
56. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferriet R, Bourguet P, Bekhechi D, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. HEPATOLOGY 1997;26:1156-1161.
57. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994;26:66-68.
58. Martinez-Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-706.
59. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917922.
60. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. HEPATOLOGY 1995;21:1535-1542.
61. CLIP Group. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998;352:17-20.
62. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, Diaz G, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26:200-203.
63. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218-222.
64. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987;71:1213-1216.
65. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric doubleblind trial. J Clin Oncol 1998;16:411417.
66. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-447.
67. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, Manno M, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-885.
68. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978;42:2149-2156.
69. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983;15:206-210.
70. Choi T, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984;53:401-405.
71. Falkson G, MacIntyre JM, Schut AJ, Coetzer B, Johnson LA, Simson IW, Douglass HO Jr. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984;6:581-584.
72. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970-977.
73. Bezwoda WR, Weaving A, Kew M, Derman DP. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. Oncology 1987;44:207-209.
74. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
75. Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ, Haller DG. A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1990;13:510-515.
76. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:452-459.
77. Lai CL, Wu PC, Lok AS, Lin HJ, Nga H, Lau JY, Chung HT, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60:928-933.
78. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. HEPATOLOGY 1993;17:389-394.
79. Falkson G, Lipsitz S, Borden E, Simson I, Haller D. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol 1995;18:287-292.
80. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. HEPATOLOGY 2000;31:1-5.
81. Lai EC, Choi TK, Tong SW, Ong GB, Wong J. Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial. World J Surg 1986;10:501-509.
82. Van der Merwe CF, Booyens J, Joubert HF, Van der Merwe CA. The effect of gammalinolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo controlled trial. Prostaglandins Leukot Essent Fatty Acids 1990;40:199-202.
83. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: metaanalysis of randomized conrrolled trials. Radiology 2002;224:47-54.
84. Lu CD, Qi YG, Peng SY. Lipiodolization with or without gelatin sponge in hepatic arterial chemoembolization for hepatocellular carcinoma. Chin Med J (Engl) 1994;107:209-215.
85. Egger M, Smith GD. Bias in location and selection of studies. Br Med J 1998;316:61-66.
86. Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, Liberati A. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2000;53:964-972.
87. Coll S, Sola R, Vila MC, Andreu M, Bory F, Vazquez D, Gana J, et al. Treatment with tamoxifen in patients with advanced hepatocellular carcinoma. Results of a randomized placebo controlled trial [Abstract]. Hepatology 1995;22:404A.
88. Barbare JC, Milan C, Bouché O, Raoul J-L, Rougier P, Bommelear G, Ducreux M, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen: a phase III trial in 420 patients [Abstract]. Proc Am Soc Clin Oncol 2002;21:138A.
89. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. HEPATOLOGY 2002;36:1221-1226.